{"id":"lf111-drospirenone","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Breast tenderness"},{"rate":null,"effect":"Breakthrough bleeding"},{"rate":null,"effect":"Mood changes"}]},"_chembl":{"chemblId":"CHEMBL3186202","moleculeType":"Small molecule","molecularWeight":"366.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Drospirenone binds to progesterone receptors in the hypothalamus and pituitary, suppressing the luteinizing hormone (LH) surge and inhibiting ovulation. It also possesses antimineralocorticoid activity, providing mild diuretic and potassium-sparing effects. In combination with ethinyl estradiol or estradiol, it is used for contraception and management of hormone-responsive conditions.","oneSentence":"Drospirenone is a progestin that acts as a progesterone receptor agonist and aldosterone antagonist, used in hormonal contraceptive formulations.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:18:52.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Oral contraception"},{"name":"Treatment of premenstrual dysphoric disorder (PMDD)"}]},"trialDetails":[{"nctId":"NCT05303636","phase":"PHASE4","title":"LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult Women","status":"RECRUITING","sponsor":"Insud Pharma","startDate":"2022-03-28","conditions":"Change in Bone Mineral Density, Bone Loss","enrollment":1710},{"nctId":"NCT02269241","phase":"PHASE3","title":"Safety, Efficacy, Tolerability and Pharmacokinetics of LF111 (Drospirenone 4.0 mg) During 13 Cycles","status":"COMPLETED","sponsor":"Laboratories Leon Farma, S.A.","startDate":"2014-10-09","conditions":"Contraception","enrollment":1552}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CF111"],"phase":"phase_3","status":"active","brandName":"LF111 (drospirenone)","genericName":"LF111 (drospirenone)","companyName":"Laboratories Leon Farma, S.A.","companyId":"laboratories-leon-farma-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Drospirenone is a progestin that acts as a progesterone receptor agonist and aldosterone antagonist, used in hormonal contraceptive formulations. Used for Oral contraception, Treatment of premenstrual dysphoric disorder (PMDD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}